Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

C. Gianna Hoffman-Luca; Chao-Yie Yang; Jianfeng Lu; Daniel Ziazadeh; Donna McEachern; Laurent Debussche; Shaomeng Wang

doi:10.1371/journal.pone.0128807

Loading metrics

Open Access

Peer-reviewed

Research Article

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

C. Gianna Hoffman-Luca,

Affiliations University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America, Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America
⨯
Chao-Yie Yang,

Affiliations University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America
⨯
Jianfeng Lu,

Affiliations University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America
⨯
Daniel Ziazadeh,

Affiliations University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America, Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America
⨯
Donna McEachern,

Affiliations University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America
⨯
Laurent Debussche,

Affiliation Sanofi Oncology, Vitry-sue-Seine, France
⨯
Shaomeng Wang

* E-mail: shaomeng@umich.edu

Affiliations University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America, Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America
⨯

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

C. Gianna Hoffman-Luca,
Chao-Yie Yang,
Jianfeng Lu,
Daniel Ziazadeh,
Donna McEachern,
Laurent Debussche,
Shaomeng Wang

Published: June 12, 2015
https://doi.org/10.1371/journal.pone.0128807

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Heterozygosity
Is the Subject Area "Heterozygosity" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Cell growth
Is the Subject Area "Cell growth" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Cell cycle and cell division
Is the Subject Area "Cell cycle and cell division" applicable to this article?

Thanks for your feedback.